

Article

Immunohistochemistry-Based Taxonomical Classification of Bladder Cancer Predicts Response to Neoadjuvant Chemotherapy

Albert Font ^{1,†}, Montserrat Domènech ^{2,†}, Raquel Benítez ³, Marta Rava ³ , Miriam Marqués ^{4,5}, José L. Ramírez ^{1,6}, Silvia Pineda ³ , Sara Domínguez-Rodríguez ³, José L. Gago ⁷, Josep Badal ⁸, Cristina Carrato ^{9,10}, Héctor López ¹¹, Ariadna Quer ⁹, Daniel Castellano ¹², Núria Malats ^{3,4,*}  and Francisco X. Real ^{4,5,13,*} 

¹ Medical Oncology Department, Institut Català d'Oncologia, Badalona Applied Research group in Oncology (B-ARGO Group), University Hospital Germans Trias i Pujol, 08916 Badalona, Spain; afont@iconcologia.net (A.F.); jramirez@iconcologia.net (J.L.R.)

² Medical Oncology Department, Fundació Althaia, 08243 Manresa, Spain; mdomenech@althaia.cat

³ Genetic and Molecular Epidemiology Group, Spanish National Cancer Research Centre (CNIO), 28029 Madrid, Spain; rbenitezd@ext.cnio.es (R.B.); rava.marta@gmail.com (M.R.); spineda@cnio.es (S.P.); sara.dominguez.r@gmail.com (S.D.-R.)

⁴ Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28029 Madrid, Spain; mmrques@cnio.es

⁵ Epithelial Carcinogenesis Group, Spanish National Cancer Research Centre (CNIO), 28029 Madrid, Spain

⁶ IGTP-Molecular Biology Laboratory, Institut Germans Trias i Pujol, 08916 Badalona, Spain

⁷ Urology Department, Hospital Universitari Germans Trias i Pujol, 08916 Badalona, Spain; zhigago@gmail.com

⁸ Pathology Department, Fundació Althaia, 08243 Manresa, Spain; jbadal@althaia.cat

⁹ Pathology Department, Hospital Germans Trias i Pujol, 08916 Badalona, Spain; ccarrato@hotmail.com (C.C.); ariadnaqs@gmail.com (A.Q.)

¹⁰ Universitat Autònoma de Barcelona, 08193 Barcelona, Spain

¹¹ Urology Department, Fundació Althaia, 08243 Manresa, Spain; hlopez@althaia.cat

¹² Medical Oncology Department, Hospital 12 de Octubre, 28029 Madrid, Spain; cdanicas@hotmail.com

¹³ Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra, 08193 Barcelona, Spain

* Correspondence: nmalats@cnio.es (N.M.); freal@cnio.es (F.X.R.), Tel.: +34-917328000 (N.M. & F.X.R.)

† These authors contribute equally to this study.

‡ These authors contribute equally to this study.

Received: 5 June 2020; Accepted: 25 June 2020; Published: 3 July 2020



Abstract: Background: Platinum-based neoadjuvant chemotherapy (NAC) increases the survival of patients with organ-confined urothelial bladder cancer (UBC). In retrospective studies, patients with basal/squamous (BASQ)-like tumors present with more advanced disease and have worse prognosis. Transcriptomics-defined tumor subtypes are associated with response to NAC. Aim: To investigate whether immunohistochemical (IHC) subtyping predicts NAC response. Methods: Patients with muscle-invasive UBC having received platinum-based NAC were identified. Tissue microarrays were used to type tumors for KRT5/6, KRT14, GATA3, and FOXA1. Outcomes: progression-free survival and disease-specific survival; univariable and multivariate Cox regression models were applied. Results: We found a very high concordance between mRNA and protein expression. Using IHC-based hierarchical clustering, we classified 126 tumors in three subgroups: BASQ-like (FOXA1/GATA3 low; KRT5/6/14 high), Luminal-like (FOXA1/GATA3 high; KRT5/6/14 low), and mixed-cluster (FOXA1/GATA3 high; KRT5/6 high; KRT14 low). Applying multivariable analyses, patients with BASQ-like tumors were more likely to achieve a pathological response to NAC (OR 3.96; $p = 0.017$). The clinical benefit appeared reflected in the lack of significant survival differences between patients with BASQ-like and luminal tumors. Conclusions: Patients with BASQ-like tumors—identified

through simple and robust IHC—have a higher likelihood of undergoing a pathological complete response to NAC. Prospective validation is required.

Keywords: bladder cancer; neoadjuvant chemotherapy; molecular taxonomy; immunohistochemistry; basal/squamous-like tumors

1. Introduction

Cisplatin-based neoadjuvant chemotherapy (NAC) is the recommended treatment for locally advanced muscle-invasive bladder cancer (MIBC), with the highest level of evidence [1]. Meta-analyses have shown that the benefit of NAC is limited to a subset of patients, with an overall improvement of 5–6.5% in 5-year survival compared to cystectomy alone [2,3]. A recent meta-analysis shows a significant overall survival (OS) benefit associated with cisplatin-based NAC (hazard ratio (HR), 0.87; 95% confidence interval (CI), 0.79–0.96) [4]. Pathological complete response (pCR) or down-staging to non-MIBC (pT1–pTis) occur in almost half of patients treated with NAC. Patients who benefit the most from NAC are those achieving a pCR at cystectomy [4,5]. The inability to select patients who can benefit has limited the use of NAC: treatment can lead to unnecessary toxicity in patients who fail to respond, and it delays a potentially curative cystectomy, with a negative survival impact [6,7]. In fact, a recent study concluded that while patients who attain a pCR have longer survival, those who do not attain a pCR have a worse prognosis than patients who proceed directly to radical cystectomy without NAC [8]. These issues have reduced the use of NAC, highlighting the need of biomarkers to identify patients likely to benefit from NAC.

A better understanding of the molecular heterogeneity of urothelial bladder cancer (UBC) [9–11] has enabled classifying MIBC patients according to molecular profiles. Several groups have proposed classifications of all [12], non muscle-invasive bladder cancer (NMIBC) [13] or MIBC [9–11,14,15] tumors according to their transcriptome. Common to them is the identification of a tumor subgroup, resembling basal-like breast cancers and lacking urothelial luminal markers. There is consensus that basal/squamous-like (BASQ) tumors can be defined using four markers: FOXA1, GATA3, KRT5/6, and KRT14. FOXA1 and GATA3 are expressed throughout the urothelium, and they are involved in the expression of the urothelial differentiation program. In contrast, KRT14 is exclusively expressed in a subset of cells in the basal layer and KRT5 is expressed in basal/suprabasal layers, but it is excluded from the most luminal layers. Using these markers, BASQ tumors have been shown to be characterized as expressing KRT5/6 and KRT14 and lacking GATA3 and FOXA1 [16].

This classification is potentially relevant from a clinical standpoint as several studies have shown that patients with BASQ-type UBC have a more advanced disease at presentation and worse prognosis [14,17,18]. However, there is also evidence from retrospective studies that these tumors may respond better to NAC [14,18,19]. The BASQ subtype was originally reported using global transcriptomics but its phenotype can be recognized with high accuracy using immunohistochemistry (IHC) [20,21].

In this retrospective study, we have assessed the relationship between MIBC tumor subtypes—identified by IHC—and the response to NAC and survival. In complementary analyses, we also examined the agreement of the results of IHC and mRNA expression. The first molecular taxonomy classification of MIBC did not include markers of luminal tumors [16], although the KRT20 expression and alterations in several genes—including *FGFR3*, *STAG2*, and *PIK3CA*—have been postulated as molecular markers of this molecular subtype [22]. It remains unclear, however, whether combining the analysis of urothelial/luminal differentiation markers with markers of basal MIBC could improve its predictive capacity. In addition, oncogene mutations have been described in MIBC [10,11]. Therefore, we included them in order to explore whether they have an added value in the prediction of response to NAC.

2. Results

2.1. Clinical-Pathological Features of Patients

This study is based on a retrospective series of patients with MIBC, treated with platinum-based NAC in two Spanish hospitals from 1994 to 2014 ($n = 215$). A fraction of patients was not analyzed; the main reason for patient exclusion was that the tumor tissue was unavailable ($n = 76$) because one of the hospitals was a referral center for other hospitals in its catchment area and the transurethral resection of the bladder tumor (TURBT) was performed elsewhere. To assess the possible selection biases, we compared the clinical-pathological characteristics between the groups of eligible vs. ineligible patients, and did not find strong evidence for the existence of major biases (Table S1). An additional seven patients were not included because of the lack of information on all four IHC markers, not allowing cluster definition. Finally, a total of 126 patients were finally assessed.

The clinical-pathological characteristics of the patients from whom tumor tissue was available and those from whom no material was available were similar, indicating that the cases analyzed were representative of the whole population. The only significant difference was the NAC regimen used, reflecting the variability related to the inclusion period (Table S1). The baseline characteristics of 126 patients with IHC data for all markers, according to the tumor clusters, are listed in Table 1. Median age was 66 (range, 61–72); 86% were pure urothelial carcinomas; the remaining 14% had mixed histology, with the predominance of squamous differentiation. Clinical staging was T2–4N0M0 for 104 (83%) patients; 21 (17%) had nodal involvement. The chemotherapy regimens used were: cisplatin and gemcitabine (CG) (63%), cisplatin, methotrexate, and vinblastine (CMV) (25%), and carboplatin and gemcitabine (CaG) (10%).

Pathologic down staging occurred in 55 (44%) patients; 39 cases (31%) had a pCR. The baseline characteristics of responders and non-responders were similar except for nodal involvement, which was more common among the non-responders (26% vs. 0%; $p = 0.002$) (Table S2).

2.2. Taxonomic Classification and Association with Gene Mutations

We first compared the Nanostring RNA quantification of the four markers with protein expression using IHC. Highly significant Pearson correlation coefficients were found for GATA3, FOXA1, and KRT14; a good correlation was found for KRT5/6 (Figure 1A).




Figure 1. (A) Comparison of the results of immunohistochemistry (IHC) findings and Nanostring expression for the markers used for the tumor subtype classification shows an excellent correlation between both assays. (B) Comparison of the histoscore of tissue microarray (TMA) cores with the findings in full sections of the corresponding transurethral resection of the bladder tumor (TURBT) full block sections.

Table 1. Patient and tumor characteristics according to the taxonomic clusters (N = 126).

Characteristics	Total N = 126	Basq_Like N = 47	Luminal_Like N = 44	Mixed N = 35	p Value
Sex					1.000
Male	118 (93.7%)	44 (93.6%)	41 (93.2%)	33 (94.3%)	
Female	8 (6.3%)	3 (6.4%)	3 (6.8%)	2 (5.7%)	
Age (Med, IQR)	66 (61–72)	66.0 (62.0;72.0)	67.0 (62.0;72.2)	65.0 (57.5;71.5)	0.481
Morphology					0.011
Urothelial (pure)	108 (85.7%)	33 (70.2%)	43 (97.7%)	32 (91.4%)	
Mixed (squamous component)	14 (11.1%)	10 (21.3%)	1 (2.27%)	3 (8.57%)	
Mixed (adenoca. component)	2 (1.6%)	2 (4.26%)	0 (0.00%)	0 (0.00%)	
Other*	2 (1.6%)	2 (4.26%)	0 (0.00%)	0 (0.00%)	
Grade					0.967
Low	3 (2.4%)	1 (2.13%)	1 (2.27%)	1 (2.86%)	
High	123 (97.6%)	46 (97.9%)	43 (97.7%)	34 (97.1%)	
Lymphovascular invasion					0.576
No	97 (77.0%)	39 (83.0%)	34 (77.3%)	24 (68.6%)	
Yes	24 (19.0%)	7 (14.9%)	9 (20.5%)	8 (22.9%)	
‘Missing’	5 (3.0%)	1 (2.13%)	2 (4.5%)	3 (8.6%)	
Hydronephrosis					0.749
No	77 (61.1%)	27 (57.4%)	27 (61.4%)	23 (65.7%)	
Yes	49 (38.9%)	20 (42.6%)	17 (38.6%)	12 (34.3%)	
cTNM					0.017
T2N0	11 (8.80%)	2 (4.35%)	9 (20.5%)	0 (0.00%)	
T3/4N0	93 (74.4%)	37 (80.4%)	27 (61.4%)	29 (82.9%)	
TxN1M0	21 (16.8%)	7 (15.2%)	8 (18.2%)	6 (17.1%)	
‘Missing’	1 (0.8%)	1 (2.1%)	0 (0.00%)	0 (0.00%)	
NAC treatment					
CG/CaG	91 (72.2)	32 (68.1)	35 (79.5)	24 (68.6)	0.014
CMV	31 (24.6)	15 (31.9)	5 (11.4)	11 (31.4)	
Other*	4 (3.2)	0	4 (9.1)	0	
pTNM					0.034
Complete	39 (31.2%)	20 (42.6%)	12 (27.3%)	7 (20.0%)	
Partial	16 (12.8%)	1 (2.1%)	8 (18.2%)	7 (20.0%)	
Not responder	70 (56%)	26 (55.3%)	23 (52.3%)	21 (60.0%)	
‘Missing’	1 (0.79)	0 (0.00%)	1 (2.27%)	0 (0.00%)	
Lymph node invasion					0.553
No	97 (80.2%)	39 (84.8%)	34 (79.1%)	24 (75.0%)	
Yes	24 (19.8%)	7 (15.2%)	9 (20.9%)	8 (25.0%)	
‘Missing’		1 (2.13%)	1 (2.27%)	3 (8.57%)	
Lymph nodes resected					0.033
0–9	67 (55.4%)	29 (63.0%)	17 (39.5%)	21 (65.6%)	
10+	54 (44.6%)	17 (37.0%)	26 (60.5%)	11 (34.4%)	
‘Missing’	5 (4%)	1 (2.13%)	1 (2.27%)	3 (8.57%)	

TNM: tumor node metastasis classification; CG: cisplatin and gemcitabine; CMV: cisplatin, methotrexate and vinblastine; CaG: Carboplatin and gemcitabine; MVAC: Methotrexate, vinblastine, adriamycin, and cisplatin; *Other: dose-dense MVAC.

IHC analysis of FOXA1 and GATA3 showed a significant positive correlation (Pearson $r = 0.68$). KRT5/6 and KRT14 levels were also significantly positively correlated ($r = 0.45$). FOXA1 and GATA3

were negatively correlated with KRT14 ($r = -0.53$ and $r = -0.62$, respectively). GATA3, but not FOXA1, levels correlated negatively with KRT5/6 ($r = -0.33$). Overall, these findings are expected based on transcriptomics-based knowledge, thus validating the IHC-based tumor typing. Inter-core histoscore concordance analysis revealed a moderate (0.4–0.6) or substantial (>0.6) agreement for all markers. Concordance was higher for the BASQ group than for the luminal or mixed groups, emphasizing that IHC is a robust tool to classify BASQ tumors.

Because our aim was to test the suitability of IHC in select patients for NAC, we used the IHC-based histoscore to subtype the cases. To prevent the need of using thresholds, hierarchical clustering was used and identified three clusters. Cluster 1 (BASQ-like) ($N = 47$) is characterized by high KRT5/6 and KRT14 levels and low FOXA1 and GATA3 levels. Cluster 2 (urothelial/luminal-like) ($N = 44$) is characterized by high FOXA1 and GATA3 levels and low KRT5/6 and KRT14 levels. Cluster 3 (mixed-cluster) ($N = 35$) is characterized by a high expression of FOXA1, GATA3 and KRT5/6, and low KRT14 levels (Figure 2A). Re-clustering of bootstrapped protein expression showed that the “BASQ-like” cluster was the most stable (stability = 0.84), indicating that this group can be most robustly identified. Classification and regression trees (CART) analysis showed that the KRT14 and KRT5/6 levels provided the best cluster discrimination (Figure 2B). In agreement with global transcriptome analyses, two tumors were identified with a low expression of all markers, but they did not form a distinct cluster, likely due to the small number.




Figure 2. Expression of FOXA1, GATA3, KRT5/6 and KRT14 in the three tumor subtypes. The heatmap depicts the relative biomarker expression. (A) Clusters resulting from the KRT5/6, KRT14, GATA3, and FOXA1 tumor histoscore. (B) Classification and regression trees (CART) model showing the optimal accuracy of the cluster classification. The numbers in the bottom boxes are the proportion of the observed clusters predicted and the percentage of UBCs each class represents.

BASQ-like tumors were enriched for the subjects with a more advanced clinical stage at diagnosis ($p = 0.013$) and mixed squamous histology ($p = 0.011$), both findings in agreement with previous data and supporting the representativeness of the tumor series. In addition, BASQ-like tumors were associated with a higher number of resected nodes ($p = 0.033$). Importantly, patients with BASQ-like tumors had a higher rate of pCR to NAC ($p = 0.034$).

The first molecular taxonomy consensus classification did not include markers of luminal/urothelial differentiation [16]. Among the candidate molecules associated with urothelial differentiation are KRT20, a well established luminal marker, and *FGFR3*, *STAG2*, and *PIK3CA*—three major bladder cancer genes commonly altered in luminal tumors [22,23]. Therefore, we analyzed these markers in the same samples. KRT20 levels were significantly lower in the BASQ tumors (Figure S1) but it was similar in the other clusters. *FGFR3* levels were significantly higher in the “mixed-cluster” tumors and the *STAG2* levels were similar in all clusters. *FGFR3* and *PIK3CA* mutations were more common in the mixed-cluster tumors but differences did not reach statistical significance. *RAS* mutations were similarly distributed across clusters (Table S3).

2.3. Association of Clusters with Response to NAC

To analyze the association with the response to NAC, we focused on the consensus markers of the BASQ-like cluster. The univariate analysis showed that the only factors significantly associated with the response to NAC were lymph node involvement ($p = 0.011$) and the BASQ-like cluster ($p = 0.035$). Of note, 16 patients (12.8%) had a pPR but only one of them had a BASQ-like tumor. The clinical variables and molecular factors associated with pCR are shown in Supplementary Table S2. The multivariate analysis of predictors of pCR, after adjusting for potential confounders, showed that the BASQ-like cluster (OR = 4.06; 95% CI 1.18–13.99) ($p = 0.026$) was significantly positively associated with pCR (Table S4).

A few patients included in the study had a lymph node involvement or received carboplatin, features that are not part of standard NAC. When these cases were excluded (sensitivity analysis), the predictive value of the BASQ-like cluster was essentially unchanged (Table S5). A fraction of the patients (24.6%) was treated with CMV combination therapy; while sample size did not allow stratified analyses, we found the same trend in the association of BASQ subtype with the outcome in this patient subgroup (Figure S2).

Mean follow-up in event-free patients was 85 months (range, 6–241); 50 patients (37.9%) progressed and 45 (34.1%) died from the disease. Figure 3 shows the Kaplan–Meier plots for relapse-free and disease-specific survival. Among all the patients, and among those who underwent a pCR, cluster classification was not associated with survival; patients with BASQ tumors having achieved a pCR had the best survival. By contrast, among the patients who did not have a pCR, those with BASQ tumors had the worst outcome ($p = 0.11$). These findings strongly suggest that the worse prognosis of patients with BASQ tumors is counteracted by a greater likelihood of displaying a pCR, resulting in the lack of differences in disease-specific survival.




Figure 3. Kaplan–Meier relapse-free survival (A–C) and disease-specific survival (D–F) curves for all patients (A,D), patients undergoing a pathological complete response (pCR) (B,E), or partial/non-responders (C,F) according to the three tumor subtypes.

2.4. Relevance to Clinical Implementation

Because the clinical implementation of the IHC classification of tumors would not rely on tissue microarrays (TMAs), we compared the marker expression in the TMAs (containing cores from the TURBT block) and in the full TURBT block sections from the corresponding tumors ($n = 15$). We found highly significant correlations for FOXA1 ($r = 0.75$), GATA3 ($r = 0.78$), and KRT14 ($r = 0.83$) and a modest correlation for KRT5/6 ($r = 0.34$) (Figure 1B). These correlations validate, overall, the usefulness of the TMAs for exploratory studies and agree with a recent publication [24].

Another level of heterogeneity relevant to clinical implementation is whether TURBT samples are representative of the deeper region of the tumor. To assess this, we compared the marker expression in full sections of paired TURBT and cystectomy specimens, from patients receiving NAC who did not achieve a pCR ($n = 17$), and in paired TURBT-cystectomy samples from patients from the same institutions who did not receive NAC ($n = 15$). In both sample series, the cystectomy samples showed a significantly reduced histoscore for luminal markers and a consistent - less prominent—increased levels of basal KRT markers. These results suggest heterogeneity in the cellular phenotypes in superficial vs. deeper tumor regions, with predominant luminal features in the TURBT samples (Figures S3 and S4). Interestingly, the trend of the changes in KRT14 levels was different in the samples that had been exposed, or not, to NAC suggesting an impact of the latter on tumor cell phenotype (Figure S5).

3. Discussion

Molecular knowledge has generated a plethora of hypotheses that could impact UBC patient management. The fact that only a fraction of patients respond to available therapies, highlights the need of improved patient stratification—especially with the advent of immunotherapy. This need is obvious for NAC, where the risk of tumor progression in non-responders has underscored its cautious application even when global survival statistics supports its use in patients with locally advanced organ-confined tumors [8].

In MIBC, several tumor subtypes have been identified; the greatest consensus exists for the BASQ-like type, defined using transcriptomics. Based on this, and on the increasing evidence that BASQ tumors are more aggressive but may respond better to chemotherapy, we performed this analysis using IHC.

To our knowledge, ours is the first study showing that a cluster of tumors with BASQ-like features, comprising approximately one-third of all patients with MIBC, can be robustly identified using simple IHC to predict the NAC response. This cluster is defined by the low/undetectable expression of GATA3/FOXA1 and the high expression of KRT5/6/14. KRT5/6 did not clearly distinguish BASQ-like tumors from the mixed-cluster tumor subtype. These markers have also previously been shown by the Lund group to robustly translate global transcriptomic classifiers into immunohistochemical assays [20]. Because of the well defined specificity of the antibodies used and the robustness of the IHC staining assays, the marker combination used here could be widely applied in the Pathology Departments of general hospitals where Nanostring technology is not available, thus facilitating the clinical translation. While it is possible that a lower number of markers could be used, at this point there is insufficient evidence for this: tumors that are broadly KRT14⁺ generally lack expression of GATA3 and FOXA1 and are unquestionably BASQ type; tumors that are KRT5/6⁺ and display a broad expression pattern are also highly likely to be BASQ-type, especially if they lack GATA3/FOXA1 expression; tumors with an expression of KRT5/6⁺ restricted to the basal layer are likely to be GATA3/FOXA1⁺. In these tumors, KRT5/6 distribution corresponds to that of the normal urothelium and therefore, they should not be considered BASQ like as highlighted by the Lund group [20].

Patients with BASQ-like tumors have a significantly higher likelihood of response to NAC in comparison to the other tumor subgroups, but only 42% of them underwent a pCR, indicating that further refinement is required to improve patient selection.

Three strategies have been applied to identify the markers of response to cisplatin-based NAC: global transcriptomics [15,18], panel IHC (first used here), and gene mutation analysis [25,26]. Two studies used global transcriptomics using formalin-fixed paraffin-embedded (FFPE) samples to define UBC subtypes in relationship to the response to NAC. Patients with basal tumors from a clinical trial with dose-dense MVAC and bevacizumab had improved survival compared to those with luminal or p53-like tumors. In that study, NAC response was not associated with tumor subtype [19]. In a large multicenter retrospective series comparing patients having undergone cystectomy without NAC and those having received NAC, the patients with basal tumors not receiving NAC consistently had worse overall survival than those with luminal tumors. Importantly, the patients with basal-like tumors (SCC-like, cluster III, or Uro B) showed the greatest improvement in outcome after NAC. In multivariate analysis, the patients with basal tumors not receiving NAC had an adjusted HR of 2.22 for OS compared to luminal tumors; these differences were eroded in the NAC cohort. Surprisingly, among the patients with basal tumors (unlike in luminal tumors), OS was similar for major responders vs. non-responders [18]. The use of group comparisons is complicated by the fact that some patients not undergoing NAC receive adjuvant chemotherapy—or eventually—receive cisplatin-based chemotherapy if they progress during follow-up.

Our study relied on the type of samples that would be used for patient stratification, i.e., TURBT. We find that a simple, robust, IHC-based typing of FFPE tumors may contribute to better select patients to receive NAC, although TURBT samples may not be completely representative of the whole tumor. The deep region thereof, sampled at cystectomy, tends to have a more basal phenotype, highlighting tumor heterogeneity. A recent study of bladder cancer histological variants has shown that BASQ tumors display the greatest heterogeneity, and supports that variants arise from conventional urothelial carcinomas [27]. More work needs to be carried out to specifically assess the relevance of sample bias, the difference between primary tumor vs. lymph node or distant metastases [25,28] as well as the biological changes associated with tumor evolution, naturally or under therapy pressure [26]. Prospective studies should determine the optimal strategy for BASQ tumor definition, considering the more recently proposed classifiers [29]. In this regard, it has been proposed that the "luminal-non-specified" subtype might also benefit from NAC. Since it is not currently possible to identify this group with IHC markers, this relevant question will have to be addressed in future studies either with RNA analyses or through improved IHC marker definition.

Regarding genomic alterations, somatic *ERCC2* mutations are enriched in NAC responders and functional in vitro studies support a causal association [30]. Genomic alterations in *RB1*, *ATM*, and *FANCC* were also predictive of a response to—and clinical benefit from—NAC [31]. The prevalence of mutations in these genes in MIBC is relatively low, and varies in different studies (*RB1* (20%, range 7–25%), *ATM* (11%, range 6–15%), *ERCC2* (10%, range 2–17%), *FANCC* (2.2%, range 1.5–3%)), and there is partial co-occurrence (source <http://www.cbiportal.org/>).

An important question is whether gene mutations are related to tumor subtypes, since this could impact the application of marker combination to predict the response to NAC. *ERCC2* mutation prevalence is similar in BASQ-like and non-BASQ-like tumors. *RB1* mutations—but not deletions—are significantly more common in BASQ-like than in urothelial tumors [9,29]. However, deletions are more common in the Lund “genomically unstable” subgroup. There is insufficient data to indicate whether *ATM* and *FANCC* alterations are enriched in any taxonomical types [9,11,29], suggesting that combined tumor subtyping and mutational analysis could improve the ability to predict NAC response.

This study has several limitations derived from its retrospective nature and not being a clinical trial, including the modest sample size and relatively long recruitment period, the lack of centralized pathology review, the inclusion of patients treated with carboplatin, possible uncontrolled differences in clinical management, and the generation of clusters based on TMA data. These limitations reflect much of the variability associated with the application of NAC in clinical practice [32,33] and have been mitigated through several types of analyses. While the P-values found are close to the threshold of significance, the OR are in the range of clinical relevance. Nevertheless, the establishment of robust

thresholds for tumor classification and the conduct of prospective clinical studies are necessary to conclusively establish the contribution of tumor subtyping to the management of patients with MIBC and the optimal clinical implementation strategy.

4. Materials and Methods

4.1. Study Design

This study included patients treated at two Spanish hospitals (Institut Català d'Oncologia, Hospital Universitari Germans Trias i Pujol (HUGTiP), Badalona; Fundació Althaia, Manresa, Barcelona). The study protocols were approved by the corresponding ethical committees [codes PI-15-072 (HUGTiP) and 15-27 (Fundació Althaia)]. MIBC was identified by the transurethral resection of the bladder tumor (TURBT). Patients clinically staged with abdominal/pelvic computed tomography (CT) and a chest X-ray, and classified as T2-4aN0-2M0, were candidates for cystectomy after NAC. pCR was defined as the absence of a detectable tumor in the cystectomy specimen (pT0N0); partial response was defined as down staging to non-MIBC (<pT2N0). Remaining cases were considered non-responders. None of the patients received adjuvant chemotherapy nor immunotherapy. Patients provided informed consent; the study was approved by the institutional review board of the two hospitals.

NAC was administered to 215 patients (1994–2014). The chemotherapy regimen was cisplatin, methotrexate, and vinblastine (CMV) until 2000, after which cisplatin and gemcitabine (CG) or—exceptionally—carboplatin and gemcitabine (CaG) was used. The final number of patients analyzed was 126 patients; the remaining patients were mainly excluded because the tumor tissue was unavailable or information on all four IHC markers was not obtained. Information was collected through a retrospective review of clinical and pathological records.

4.2. Immunohistochemical Analyses

TURBT formalin-fixed paraffin-embedded (FFPE) blocks were reviewed. Representative tumor areas were selected to extract 3 cores and construct tissue microarrays (TMAs). Cores were positioned non-consecutively to avoid artefacts; TMAs were constructed following the established guidelines and sectioned; and the slides were embedded in paraffin and stored at 4 °C. The following antibodies were used: KRT5/6 (PRB-160P, Covance; 1/2000), KRT14 (PRB-155P, Covance, 1/2000), GATA3 (CM405 A, Biocare Medical, 1/300), FOXA1 (ab170933, Abcam, 1/100), FGFR3 (B9, Santa Cruz), KRT20 (Ks20.8, Dako), and STAG2 (J-12, Santa Cruz). After deparaffinization, antigen retrieval, and endogenous peroxidase blockade, the sections were incubated with antibodies overnight, washed, and Envision secondary reagents (Agilent) were added for 1 h. After washing, the reactions were developed with DAB, the sections were counterstained with hematoxylin, and mounted. Scoring was performed blind to clinical/pathological information by an experienced investigator (FXR). The proportion of reactive cells (0–100%) and staining intensity (0–3) were recorded; the histoscore was calculated as the product: Intensity × % reactive cells (range 0–300). The average of the scores was used for analysis.

4.3. RNA Expression Analyses

Total RNA was isolated from the full FFPE sections and purified from macrodissected high-density tumor areas using the truxTrac FFPE RNA microTube kit (Covaris, Woburn, MA, USA). Cell lysates were sheared by sonication; RNA was eluted and quantified using Qubit. Gene expression analysis was conducted on the NanoString nCounter platform. Samples were scanned at maximum resolution on the nCounter Digital Analyzer. Four housekeeping transcripts were used for normalization (*GAPDH*, *ACTB*, *HPRT1*, and *LDHA*).

4.4. Mutational Analyses

Hotspot mutations in *FGFR3* (R248C, S249C, G372C, S373C, Y375C, G382R, A393E, K652E/Q/T/M), *PIK3CA* (E542K, E545K/Q/G, H1047L/R), *HRAS* (G12C/S/D/V, G13C/R, Q61K/L/R),

KRAS (G12C/R/S/A/D/V, Q61E), and *NRAS* (G12/R, Q61/L/R) were assessed. DNA was extracted from the tumor cell-enriched areas using a DNeasy tissue kit (Qiagen, Hilde, Germany). Multiplex PCRs were performed; the products were analyzed with the a SNaPshot Multiplex Kit (Applied Biosystems) [22].

4.5. Statistical Methods

All the analyses performed were specified a priori and corresponded to specific hypotheses. Variables were summarized as the means, medians, and standard deviations—when continuous—and as percentages when categorical. Bivariable associations were evaluated by the chi2 test (categorical) and the Kruskal–Wallis test (continuous). The Pearson test was applied to assess the correlations. Agglomerative hierarchical clustering was applied using the Ward's minimum variance method to investigate the evidence for the natural groupings of tumor (subtypes) based on the correlations between expression profiles. Histoscores were standardized to a 0–1 range and considered as input. Heatmaps were generated using pHeatmap [34]. To investigate cluster stability, bootstrapped histoscore values were re-clustered and their similarity with the original classification was evaluated with the Jaccard coefficient [35]. The CART model was trained considering the 3 clusters and the 4 markers using the caret and rpart packages. Leave-one-out cross validation was used to evaluate the best prediction scenario.

Adjusted logistic regression was applied to assess the independent association between the clusters and response. For each variable, the odds ratio (OR) was estimated referring to the association between the predictor pCR with the 'no-complete response' group—including partial responders and non-responders—as the reference. Sensitivity analyses were run after excluding subjects with pelvic lymph node involvement or treated with carboplatin (N = 31).

Survival curves were derived using Kaplan–Meier methods and compared with log-rank tests by strata defined by the tumor subtypes obtained with the cluster analysis. Disease-specific survival and progression-free survival were considered as outcomes. Hazard ratios and 95% confidence interval for the association between the subtypes and the outcomes were estimated with univariable and multivariable Cox regression models.

Differences were considered statistically significant at two-sided $p < 0.05$. All statistical analyses were performed using R version 3.3 (<https://www.r-statistics.com/tag/r-3-3-0/>) unless otherwise indicated. Data availability statement: All data from this study are available upon reasonable request to authors.

5. Conclusions

This retrospective study shows that patients with BASQ-like tumors can be identified using immunohistochemistry on paraffin-embedded tissue and are 4-fold more likely to achieve a pathological complete response to platinum-based NAC. The disease-specific survival of patients with BASQ-like tumors treated with NAC was not different from that of other tumor subtypes. Prospective studies are required to confirm these observations and determine the clinical value of tumor subtyping.

Supplementary Materials: The following are available online at <http://www.mdpi.com/2072-6694/12/7/1784/s1>, Table S1: Characteristics of the subjects included and excluded from the analyses, Table S2: Patient characteristics according to the response to treatment (N = 131)*, Table S3: Distribution of bladder cancer gene mutations according to the 3 clusters identified (N = 126), Table S4: Predictive factors of complete response to neoadjuvant treatment. Multivariate logistic regression models (N = 126), Table S5: Predictive factors of pCR to NAC. Multivariate logistic regression models (N = 100)*, Figure S1: Median and interquartile range (IQR) of HS corresponding to each tumor marker according to the 3 clusters identified (N = 126), Figure S2: Kaplan–Meier relapse-free survival (left panels) and disease-specific survival (right panels) curves for patients treated with CG/CaG (A) vs. CMV (B) combination therapy. Figure S3: Comparison of marker expression in full sections of samples obtained at TURBT and cystectomy (Cys) from patients treated with NAC. Figure S4: Comparison of marker expression in full sections of samples obtained at TURBT and cystectomy (Cys) from patients who did not receive NAC. Figure S5: Interaction analysis of marker expression in full sections of samples obtained at TURBT and cystectomy (Cys) from patients treated (orange) or not (blue) with NAC.

Author Contributions: Conceptualization, A.F., M.D., D.C., N.M. and F.X.R.; formal analysis, R.B., M.R., S.P., S.D.-R., N.M.; investigation, M.M., J.L.R. and F.X.R.; resources, J.L.G., J.B., C.C., H.L. and A.Q.; data curation, R.B., M.R. and N.M.; writing—original draft preparation, A.F., M.D., N.M. and F.X.R.; writing—review and editing, R.B., M.R., M.M., J.L.R., S.P., S.D.-R., J.L.G., C.C. and D.C.; supervision, N.M., F.X.R.; funding acquisition, A.F., D.C., N.M. and F.X.R. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported, in part, by a grant from Asociación Española Contra el Cáncer to FXR, NM, AF, and DC; Fondo de Investigaciones Sanitarias (FIS), Instituto de Salud Carlos III-FEDER (Grant PI18/01347 to NM) and Red Temática de Investigación Cooperativa en Cáncer, Spain (#RD12/0036/0034, #RD12/0036/0050 to NM and FXR). The funders had no role in the study design, data collection, management, or analysis and interpretation of the data.

Acknowledgments: We thank Tania Lobato, José M. Velarde, and Natalia del Pozo for valuable contributions.

Conflicts of Interest: Authors have no financial disclosures or other conflict of interest.

Abbreviations

BASQ-like	basal/squamous-like
CART	classification and regression trees
FFPE	formalin-fixed paraffin-embedded
IHC	immunohistochemistry
MIBC	muscle-invasive bladder cancer
NAC	neoadjuvant chemotherapy
OS	overall survival
pCR	pathological complete response
TMA	tissue microarrays
TURBT	transurethral resection of the bladder tumor
UBC	urothelial bladder cancer

References

1. Witjes, J.A.; Lebre, T.; Compérat, E.M.; Cowan, N.C.; De Santis, M.; Bruins, H.M.; Hernández, V.; Espinós, E.L.; Dunn, J.; Rouanne, M.; et al. Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer. *Eur. Urol.* **2017**, *71*, 462–475. [\[CrossRef\]](#)
2. Winquist, E.; Kirchner, T.S.; Segal, R.; Chin, J.; Lukka, H. Genitourinary Cancer Disease Site Group. Cancer Care Ontario Program in Evidence-based Care Practice Guidelines Initiative. Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: A systematic review and meta-analysis. *J. Urol.* **2004**, *171*, 561–569. [\[CrossRef\]](#)
3. Milowsky, M.I.; Rumble, R.B.; Booth, C.M.; Gilligan, T.; Eapen, L.J.; Hauke, R.J.; Boumansour, P.; Lee, C.T. Guideline on Muscle-Invasive and Metastatic Bladder Cancer (European Association of Urology Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement. *J. Clin. Oncol.* **2016**, *34*, 1945–1952. [\[CrossRef\]](#) [\[PubMed\]](#)
4. Yin, M.; Joshi, M.; Meijer, R.P.; Glantz, M.; Holder, S.; Harvey, H.A.; Kaag, M.; Fransen van de Putte, E.E.; Horenblas, S.; Drabick, J.J. Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Systematic Review and Two-Step Meta-Analysis. *Oncologist* **2016**, *21*, 708–715. [\[CrossRef\]](#) [\[PubMed\]](#)
5. Grossman, H.B.; Natale, R.B.; Tangen, C.M.; Speights, V.O.; Vogelzang, N.J.; Trump, D.L.; de Vere White, R.W.; Sarosdy, M.F.; Wood, D.P., Jr.; Raghavan, D.; et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. *N. Engl. J. Med.* **2003**, *349*, 859–866. [\[CrossRef\]](#)
6. Sánchez-Ortiz, R.F.; Huang, W.C.; Mick, R.; Van Arsdalen, K.N.; Wein, A.J.; Malkowicz, S.B. An interval longer than 12 weeks between the diagnosis of muscle invasion and cystectomy is associated with worse outcome in bladder carcinoma. *J. Urol.* **2003**, *169*, 110–115. [\[CrossRef\]](#)
7. Lee, C.T.; Madii, R.; Daignault, S.; Dunn, R.L.; Zhang, Y.; Montie, J.E.; Wood, D.P., Jr. Cystectomy delay more than 3 months from initial bladder cancer diagnosis results in decreased disease specific and overall survival. *J. Urol.* **2006**, *175*, 1262–1267. [\[CrossRef\]](#)

8. Bhindi, B.; Frank, I.; Mason, R.J.; Tarrell, R.F.; Thapa, P.; Cheville, J.C.; Costello, B.A.; Pagliaro, L.C.; Karnes, R.J.; Thompson, R.H.; et al. Oncologic Outcomes for Patients with Residual Cancer at Cystectomy Following Neoadjuvant Chemotherapy: A Pathologic Stage-matched Analysis. *Eur. Urol.* **2017**, *72*, 660–664. [[CrossRef](#)]
9. Choi, W.; Ochoa, A.; McConkey, D.J.; Aine, M.; Höglund, M.; Kim, W.Y.; Real, F.X.; Kiltie, A.E.; Milsom, I.; Dyrskjöt, L.; et al. Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas Dataset. *Eur. Urol.* **2017**, *72*, 354–365. [[CrossRef](#)]
10. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. *Nature* **2014**, *507*, 315–322. [[CrossRef](#)]
11. Robertson, A.G.; Kim, J.; Al-Ahmadie, H.; Bellmunt, J.; Guo, G.; Cherniack, A.D.; Hinoue, T.; Laird, P.W.; Hoadley, K.A.; Akbani, R.; et al. TCGA Research Network. Comprehensive molecular characterization of muscle-invasive bladder cancer. *Cell* **2017**, *171*, 540–556. [[CrossRef](#)] [[PubMed](#)]
12. Sjödaahl, G.; Lauss, M.; Lövgren, K.; Chebil, G.; Gudjonsson, S.; Veerla, S.; Patschan, O.; Aine, M.; Fernö, M.; Ringnér, M.; et al. A molecular taxonomy for urothelial carcinoma. *Clin. Cancer Res.* **2012**, *18*, 3377–3386. [[CrossRef](#)] [[PubMed](#)]
13. Hedegaard, J.; Lamy, P.; Nordentoft, I.; Algaba, F.; Høyer, S.; Ulhøi, B.P.; Vang, S.; Reinert, T.; Hermann, G.G.; Mogensen, K.; et al. Comprehensive Transcriptional Analysis of Early Stage Urothelial Carcinoma. *Cancer Cell* **2016**, *30*, 27–42. [[CrossRef](#)] [[PubMed](#)]
14. Damrauer, J.S.; Hoadley, K.A.; Chism, D.D.; Fan, C.; Tiganelli, C.J.; Wobker, S.E.; Yeh, J.J.; Milowsky, M.I.; Iyer, G.; Parker, J.S.; et al. Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. *Proc. Natl. Acad. Sci. USA* **2014**, *111*, 3110–3115. [[CrossRef](#)]
15. Choi, W.; Porten, S.; Kim, S.; Willis, D.; Plimack, E.R.; Hoffman-Censits, J.; Roth, B.; Cheng, T.; Tran, M.; Lee, I.L.; et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. *Cancer Cell* **2014**, *25*, 152–165. [[CrossRef](#)]
16. Lerner, S.P.; McConkey, D.J.; Hoadley, K.A.; Chan, K.S.; Kim, W.Y.; Radvanyi, F.; Höglund, M.; Real, F.X. Bladder cancer molecular taxonomy: Summary from a Consensus meeting. *Bladder Cancer* **2016**, *2*, 37–47. [[CrossRef](#)]
17. Rebouissou, S.; Bernard-Pierrot, I.; de Reyniès, A.; Lepage, M.L.; Krucker, C.; Chapeaublanc, E.; Héroult, A.; Kamoun, A.; Caillaud, A.; Letouzé, E.; et al. EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype. *Sci. Transl. Med.* **2014**, *6*, 244ra291. [[CrossRef](#)]
18. Seiler, R.; Ashab, H.A.D.; Erho, N.; van Rhijn, B.W.G.; Winters, B.; Douglas, J.; Van Kessel, K.E.; van de Putte, F.E.E.; Sommerlad, M.; Wang, N.Q.; et al. Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy. *Eur. Urol.* **2017**, *72*, 544–554. [[CrossRef](#)]
19. McConkey, D.J.; Choi, W.; Shen, Y.; Lee, I.L.; Porten, S.; Matin, S.F.; Kamat, A.M.; Corn, P.; Millikan, R.E.; Dinney, C.; et al. A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naïve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine; Doxorubicin; and Cisplatin with Bevacizumab in Urothelial Cancer. *Eur. Urol.* **2016**, *69*, 855–862.
20. Sjödaahl, G.; Eriksson, P.; Liedberg, F.; Höglund, M. Molecular classification of urothelial carcinoma: Global mRNA classification versus tumour-cell phenotype classification. *J. Pathol.* **2017**, *242*, 113–215. [[CrossRef](#)]
21. Dadhania, V.; Zhang, M.; Zhang, L.; Bondaruk, J.; Majewski, T.; Siefker-Radtke, A.; Guo, C.C.; Dinney, C.; Cogdell, D.E.; Zhang, S.; et al. Meta-Analysis of the Luminal and Basal Subtypes of Bladder Cancer and the Identification of Signature Immunohistochemical Markers for Clinical Use. *EBioMedicine* **2016**, *12*, 105–117. [[CrossRef](#)] [[PubMed](#)]
22. Kompier, L.C.; Lurkin, I.; van der Aa, M.N.M.; van Rhijn, B.W.G.; van der Kwast, T.H.; Zwarthoff, E.C. FGFR3, HRAS, KRAS, NRAS and PIK3CA Mutations in Bladder Cancer and Their Potential as Biomarkers for Surveillance and Therapy. *PLoS ONE* **2010**, *5*, e13821. [[CrossRef](#)] [[PubMed](#)]
23. Balbás-Martínez, C.; Sagrera, A.; Carrillo-de-Santa-Pau, E.; Earl, J.; Márquez, M.; Vazquez, M.; Lapi, E.; Castro-Giner, F.; Beltran, S.; Bayés, M.; et al. Recurrent inactivation of STAG2 in bladder cancer is not associated with aneuploidy. *Nat. Genet.* **2013**, *45*, 1464–1469. [[CrossRef](#)] [[PubMed](#)]

24. Jakobsson, L.; Chebil, G.; Marzouka, N.A.; Liedberg, F.; Sjö Dahl, G. Low Frequency of Intratumour Heterogeneity in Bladder Cancer Tissue Microarrays. *Bladder Cancer* **2018**, *4*, 327–337. [[CrossRef](#)] [[PubMed](#)]
25. Sjö Dahl, G.; Jackson, C.L.; Bartlett, J.M.; Siemens, D.R.; Berman, D.M. Molecular profiling in muscle-invasive bladder cancer: More than the sum of its parts. *J. Pathol.* **2019**, *247*, 563–573. [[CrossRef](#)]
26. Seiler, R.; Gibb, E.A.; Wang, N.Q.; Oo, H.Z.; Lam, H.M.; van Kessel, K.E.; Voskuilen, C.S.; Winters, B.; Erho, N.; Takhar, M.M.; et al. Divergent Biological Response to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Cancer. *Clin. Cancer Res.* **2018**, *25*, 5082–5093. [[CrossRef](#)]
27. Warrick, J.I.; Sjö Dahl, G.; Kaag, M.; Raman, J.D.; Merrill, S.; Shuman, L.; Chen, G.; Walter, V.; DeGraff, D.J. Intratumoural Heterogeneity of Bladder Cancer by Molecular Subtypes and Histologic Variants. *Eur. Urol.* **2019**, *75*, 18–22. [[CrossRef](#)]
28. Sjö Dahl, G.; Eriksson, P.; Lövgren, K.; Marzouka, N.A.; Bernardo, C.; Nordentoft, I.; Dyrskjöt, L.; Liedberg, F.; Höglund, M. Discordant molecular subtype classification in the basal-squamous subtype of bladder tumours and matched lymph-node metastases. *Mod. Pathol.* **2018**, *31*, 1869–1881. [[CrossRef](#)] [[PubMed](#)]
29. Kamoun, A.; de Reyniès, A.; Allory, Y.; Sjö Dahl, G.; Robertson, A.G.; Seiler, R.; Hoadley, K.A.; Groeneveld, C.S.; Al-Ahmadie, H.; Choi, W.; et al. For the Bladder Cancer Molecular Taxonomy Group. The consensus molecular classification of muscle-invasive bladder cancer. *Eur. Urol.* **2019**, *77*, 420–433. [[CrossRef](#)]
30. Van Allen, E.M.; Mouw, K.W.; Kim, P.; Iyer, G.; Wagle, N.; Al-Ahmadie, H.; Zhu, C.; Ostrovskaya, I.; Kryukov, G.V.; O'Connor, K.W.; et al. Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. *Cancer Discov.* **2014**, *4*, 1140–1153. [[CrossRef](#)]
31. Plimack, E.R.; Dunbrack, R.L.; Brennan, T.A.; Andrade, M.D.; Zhou, Y.; Serebriiskii, I.G.; Slifker, M.; Alpaugh, K.; Dulaimi, E.; Palma, N.; et al. Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer. *Eur. Urol.* **2015**, *68*, 959–967. [[CrossRef](#)] [[PubMed](#)]
32. Zargar, H.; Espiritu, P.N.; Fairey, A.S.; Mertens, L.S.; Dinney, C.P.; Mir, M.C.; Krabbe, L.M.; Cookson, M.S.; Jacobsen, N.E.; Gandhi, N.M.; et al. Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer. *Eur. Urol.* **2015**, *67*, 241–249. [[CrossRef](#)] [[PubMed](#)]
33. Peyton, C.C.; Tang, D.; Reich, R.R.; Azizi, M.; Chipollini, J.; Pow-Sang, J.M.; Manley, B.; Spiess, P.E.; Poch, M.A.; Sexton, W.J.; et al. Downstaging and survival outcomes associated with neoadjuvant chemotherapy regimens among patients treated with cystectomy for muscle-invasive bladder cancer. *JAMA Oncol.* **2018**, *4*, 1535–1542. [[CrossRef](#)] [[PubMed](#)]
34. Kolde, R. *Pheatmap: Pretty Heatmaps*, R Package Version 61, R Package: Madison WI, USA **2012**.
35. Hennig, C. Cluster-wise assessment of cluster stability. *Comput. Stat. Data Anal.* **2007**, *52*, 258–271. [[CrossRef](#)]

